Search company, investor...

Rani Therapeutics

Founded Year




Total Raised


Date of IPO


About Rani Therapeutics

Rani Therapeutics (NASDAQ: RANI) develops a robotic pill for the oral delivery of peptides, proteins, and therapeutic antibodies, which to date can only be delivered through injections. Rani's "robotic" pill is a sophisticated device, enabling it to navigate through the stomach and enter the small intestine. The RaniPill capsule goes through a transformation and aligns itself and injects the drug into the intestinal wall.

Headquarters Location

2051 Ringwood Ave.

San Jose, California, 95131,

United States


Missing: Rani Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Rani Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Rani Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Rani Therapeutics is included in 3 Expert Collections, including Medical Devices.


Medical Devices

8,633 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Health IT

7,901 items

Rani Therapeutics Patents

Rani Therapeutics has filed 107 patents.

The 3 most popular patent topics include:

  • Digestive system
  • Drug delivery devices
  • Medical equipment
patents chart

Application Date

Grant Date


Related Topics




Digestive system, Medical equipment, Gastrointestinal tract disorders, Drug delivery devices, Pharmacokinetics


Application Date


Grant Date



Related Topics

Digestive system, Medical equipment, Gastrointestinal tract disorders, Drug delivery devices, Pharmacokinetics



Latest Rani Therapeutics News

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

May 24, 2023

San Jose, California, UNITED STATES SAN JOSE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has appointed Kate McKinley as its Chief Business Officer. “Kate is a seasoned industry leader, and we are thrilled to welcome her to Rani’s executive team,” said Talat Imran, Chief Executive Officer of Rani. “Kate’s expertise in corporate strategy, business development and commercialization will further strengthen our leadership team and partnering efforts, while positioning the Company for its next stage of growth. Kate will have a vital role in shaping our growth and external innovation strategy to further realize the full potential and value of our pipeline and our foundational RaniPill® platform technology.” Throughout her more than 20-year career developing high-performing teams in the biopharmaceutical industry, Ms. McKinley has held leadership roles with increasing responsibility in executive leadership, corporate strategy, business development, alliance management, commercial, supply chain and medical affairs. She has proven success securing global partnerships and executing regulatory and commercial strategies in biologics, cell therapies and small molecules across multiple therapeutic areas. Prior to joining Rani, Ms. McKinley was the Founder and Chief Executive Officer of Spark Outcomes, where she served as a fractional executive and corporate adviser for early-stage pharmaceutical, diagnostics, and health tech start-ups. In 2021, Kate was appointed to the role of Chief Executive Officer and to the Board of Directors of Elevar Therapeutics. She joined Elevar Therapeutics in 2019 as Chief Commercial Officer, where she scaled up and led the company’s global business development, commercial, medical affairs, manufacturing, supply chain, alliance management and corporate communications organizations. Earlier in her career, Ms. McKinley held roles of increasing responsibility in commercial and business development at Dendreon, AbbVie and Abbott. Ms. McKinley is a summa cum laude graduate of The University of Tulsa. She holds an MBA from The University of Tulsa’s Collins College of Business and a Bachelor of Science in Business Administration with degrees in Marketing, Management and Psychology. She currently serves on the Board of Directors of Maxwell Biosciences and as Chair of the Investment Committee, and was previously a member of the Board of Directors of Elevar Therapeutics and Hainan Pactil Advanced Therapeutics Company Ltd. “I am thrilled to join Rani Therapeutics at this exciting stage in its journey, and for the opportunity to work with such a talented executive team,” said Ms. McKinley. “Rani provides a unique value proposition for drug delivery by replacing painful injections with its RaniPill® capsule. I believe this technology has potential across an incredibly broad range of injectable therapeutics, which should be attractive to both patients and drug developers alike.” About Rani Therapeutics Rani Therapeutics is a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the strengthening of Rani’s leadership team and partnering efforts, Rani’s ability to secure partnerships with other companies, the advancement of Rani’s pipeline and RaniPill® platform technology, the attractiveness of the RaniPill® platform technology to patients and drug developers, and Rani’s growth as a company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “may,” “will,” “potential,” “should be,” “next stage,” “intend” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rani’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rani’s business in general and the other risks described in Rani’s filings with the Securities and Exchange Commission, including Rani’s annual report on Form 10-K for the year ended December 31, 2022, and subsequent filings and reports by Rani. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Rani undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Investor Contact:

Rani Therapeutics Frequently Asked Questions (FAQ)

  • When was Rani Therapeutics founded?

    Rani Therapeutics was founded in 2012.

  • Where is Rani Therapeutics's headquarters?

    Rani Therapeutics's headquarters is located at 2051 Ringwood Ave., San Jose.

  • What is Rani Therapeutics's latest funding round?

    Rani Therapeutics's latest funding round is IPO.

  • How much did Rani Therapeutics raise?

    Rani Therapeutics raised a total of $227M.

  • Who are the investors of Rani Therapeutics?

    Investors of Rani Therapeutics include InCube Ventures, Google Ventures, AstraZeneca, BossaNova Investimentos, Ping An Venture Capital and 16 more.

  • Who are Rani Therapeutics's competitors?

    Competitors of Rani Therapeutics include Biograil and 1 more.

Compare Rani Therapeutics to Competitors

Lyndra Therapeutics Logo
Lyndra Therapeutics

Lyndra Therapeutics aims to improve healthcare outcomes through oral, ultra-long-acting, sustained-release therapies that change how people take medicines. Instead of taking medications daily or more frequently, doses would be administered weekly or monthly, improving medication adherence for better health outcomes and lower healthcare costs. Delivering controlled amounts of medicine would also reduce side effects and improve drug efficacy.

FierceHealthcare Logo

FierceHealthcare delivers healthcare news at the intersection of business and policy. It is based in Washington, DC.

SmartTab Logo

SmartTab is a digital health company that develops targeted, precision prescription drug delivery systems. The company's ingestible wireless remote-controlled drug delivery system delivers drug dosages at precise times to precise locations in the human body.


Biograil is a Danish start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device avoids mechanical moving components and makes use of the body’s own peristaltic forces to facilitate the delivery of the biologic efficiently into the gastrointestinal wall.

Progenity Logo

Progenity (NASDAQ: PROG) is a biotechnology company with a presence in women's health molecular testing and a pipeline of proprietary tests and therapeutic applications. Progenity has a portfolio of technologies and tests for pre-eclampsia, genetic carrier testing, inheritable cancer genetics, liquid biopsy and noninvasive prenatal testing (NIPT), all designed to support clinicians in providing excellent patient care.


Company commercialising products for the treatment of periodontal disease and for use in oral surgery.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.